Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01350 (
gastrin
)
9,683
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Peptide YY
(
PYY
) is a 36 amino acid, straight chain polypeptide, which is co-localized with GLP-1 in the L-type endocrine cells of the GI mucosa.
PYY
shares structural homology with neuropeptide Y (NPY) and pancreatic polypeptide (PP), and together form the Neuropeptide Y Family of Peptides, which is also called the Pancreatic Polypeptide-Fold Family of Peptides.
PYY
release is stimulated by intraluminal nutrients, including glucose, bile salts, lipids, short-chain fatty acids and amino acids. Regulatory peptides such as cholecystokinin (CCK), vasoactive intestinal polypeptide (VIP),
gastrin
and GLP-1 modulate
PYY
release. The proximal GI tract may also participate in the regulation of
PYY
release through vagal fibers. After release, dipeptidyl peptidase IV (DPP-IV; CD 26) cleaves the N-terminal tyrosine-proline residues forming
PYY
(3-36).
PYY
(1-36) represents about 60% and
PYY
(3-36) 40% of circulating
PYY
.
PYY
acts through Y-receptor subtypes: Y1, Y2, Y4 and Y5 in humans.
PYY
(1-36) shows high affinity to all four receptors while
PYY
(3-36) is a specific Y2 agonist.
PYY
inhibits many GI functions, including gastric acid secretion, gastric emptying, small bowel and colonic chloride secretion, mouth to cecum transit time, pancreatic exocrine secretion and pancreatic insulin secretion.
PYY
also promotes postprandial naturesis and elevates systolic and diastolic blood pressure.
PYY
(1-36) and
PYY
(3-36) cross the blood-brain barrier and participate in appetite and weight control regulation.
PYY
(1-36) acting through Y1- and Y5-receptors increases appetite and stimulates weight gain.
PYY
(3-36) acting through Y2-receptors on NPY-containing cells in the arcuate nucleus inhibits NPY release and, thereby, decreases appetite and promotes weight loss.
PYY
may play a primary role in the appetite suppression and weight loss observed after bariatric operations.
...
PMID:Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. 1668 37
This paper provides quantitative data on the distributions of enteroendocrine cells (EEC), defined by the hormones they contain, patterns of colocalisation between hormones and EEC relations to nerve fibres in the rat gastric mucosa. The rat stomach has three mucosal types: non-glandular stratified squamous epithelium of the fundus and esophageal groove, a region of oxyntic glands in the corpus, and pyloric glands of the antrum and pylorus. Ghrelin and histamine were both contained in closed cells, not contacting the lumen, and were most numerous in the corpus.
Gastrin
cells were confined to the antrum, and 5-hydroxytryptamine (5-HT) and somatostatin cells were more frequent in the antrum than the corpus. Most somatostatin cells had basal processes that in the antrum commonly contacted
gastrin
cells.
Peptide YY
(
PYY
) cells were rare and mainly in the antrum. The only numerous colocalisations were 5-HT and histamine,
PYY
and
gastrin
and
gastrin
and histamine in the antrum, but each of these populations was small. Peptide-containing nerve fibres were found in the mucosa. One of the most common types was vasoactive intestinal peptide (VIP) fibres. High-resolution analysis showed that ghrelin cells were closely and selectively approached by VIP fibres. In contrast,
gastrin
cells were not selectively innervated by VIP or CGRP fibres. The study indicates that there are distinct populations of gastric EEC and selective innervation of ghrelin cells. It also shows that, in contrast to EEC of the small intestine, the majority of EEC within the stomach contained only a single hormone.
...
PMID:Distributions and relationships of chemically defined enteroendocrine cells in the rat gastric mucosa. 3104 87
<< Previous
1
2